X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse STRIDES PHARMA SCIENCE with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs ADCOCK INGRAM (S. Africa) - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 STRIDES PHARMA SCIENCE   ADCOCK INGRAM
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
ADCOCK INGRAM
Jun-14
STRIDES PHARMA SCIENCE/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,147358-   
Low Rs642258-   
Sales per share (Unadj.) Rs317.2106.5-  
Earnings per share (Unadj.) Rs7.8-26.8-  
Cash flow per share (Unadj.) Rs25.1-22.2-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.383.6-  
Shares outstanding (eoy) m89.50168.78-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.82.9 97.4%   
Avg P/E ratio x114.0-11.5 -993.0%  
P/CF ratio (eoy) x35.7-13.9 -257.7%  
Price / Book Value ratio x3.33.7 88.5%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,05852,027 153.9%   
No. of employees `0002.54.3 58.4%   
Total wages/salary Rs m4,3413,265 132.9%   
Avg. sales/employee Rs Th11,325.84,188.6 270.4%   
Avg. wages/employee Rs Th1,731.4760.6 227.6%   
Avg. net profit/employee Rs Th280.1-1,055.4 -26.5%   
INCOME DATA
Net Sales Rs m28,39417,982 157.9%  
Other income Rs m941126 747.0%   
Total revenues Rs m29,33418,108 162.0%   
Gross profit Rs m3,965-3,116 -127.3%  
Depreciation Rs m1,540776 198.5%   
Interest Rs m1,962487 402.9%   
Profit before tax Rs m1,403-4,253 -33.0%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97266 36.6%   
Profit after tax Rs m702-4,531 -15.5%  
Gross profit margin %14.0-17.3 -80.6%  
Effective tax rate %6.9-6.2 -111.0%   
Net profit margin %2.5-25.2 -9.8%  
BALANCE SHEET DATA
Current assets Rs m24,83613,170 188.6%   
Current liabilities Rs m18,9937,410 256.3%   
Net working cap to sales %20.632.0 64.2%  
Current ratio x1.31.8 73.6%  
Inventory Days Days71111 64.0%  
Debtors Days Days113124 91.5%  
Net fixed assets Rs m34,2897,677 446.7%   
Share capital Rs m89583 1,072.0%   
"Free" reserves Rs m23,6510-   
Net worth Rs m24,54614,114 173.9%   
Long term debt Rs m15,5134,960 312.8%   
Total assets Rs m65,43726,662 245.4%  
Interest coverage x1.7-7.7 -22.2%   
Debt to equity ratio x0.60.4 179.8%  
Sales to assets ratio x0.40.7 64.3%   
Return on assets %4.1-15.2 -26.8%  
Return on equity %2.9-32.1 -8.9%  
Return on capital %6.9-19.8 -34.8%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m14,9620-   
CASH FLOW
From Operations Rs m1,8711,535 121.9%  
From Investments Rs m5,826-471 -1,236.2%  
From Financial Activity Rs m-10,1574,501 -225.6%  
Net Cashflow Rs m-2,6155,565 -47.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.94 Rs / ZAR

Compare STRIDES PHARMA SCIENCE With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare STRIDES PHARMA SCIENCE With: PIRAMAL ENTERPRISES  GLENMARK PHARMA  CIPLA  J.B.CHEMICALS  PFIZER  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views On News

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks (Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock (The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Jul 19, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - GLENMARK PHARMA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS